NZ707081A - Agent for preventing or improving decline in brain function - Google Patents
Agent for preventing or improving decline in brain functionInfo
- Publication number
- NZ707081A NZ707081A NZ707081A NZ70708113A NZ707081A NZ 707081 A NZ707081 A NZ 707081A NZ 707081 A NZ707081 A NZ 707081A NZ 70708113 A NZ70708113 A NZ 70708113A NZ 707081 A NZ707081 A NZ 707081A
- Authority
- NZ
- New Zealand
- Prior art keywords
- decreased
- agent
- brain function
- salt
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012238542 | 2012-10-30 | ||
| PCT/JP2013/080053 WO2014069667A1 (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ707081A true NZ707081A (en) | 2019-03-29 |
Family
ID=50627559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ707081A NZ707081A (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10905705B2 (OSRAM) |
| EP (1) | EP2914270B1 (OSRAM) |
| JP (1) | JP6166786B2 (OSRAM) |
| AU (1) | AU2013339058B2 (OSRAM) |
| CA (1) | CA2889109C (OSRAM) |
| ES (1) | ES2906614T3 (OSRAM) |
| NZ (1) | NZ707081A (OSRAM) |
| PL (1) | PL2914270T3 (OSRAM) |
| WO (1) | WO2014069667A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2906614T3 (es) | 2012-10-30 | 2022-04-19 | Kyowa Hakko Bio Co Ltd | Agente para evitar o mejorar el deterioro de la función cerebral |
| US11583546B2 (en) * | 2014-04-30 | 2023-02-21 | Kyowa Hakko Bio Co., Ltd. | Administration of citicoline to improve cognitive performance, attentional performance, and motor function |
| CN117069780A (zh) | 2016-10-06 | 2023-11-17 | 协和发酵生化株式会社 | 胞苷二磷酸胆碱的晶体及其制造方法 |
| JP7142284B2 (ja) * | 2017-06-06 | 2022-09-27 | 株式会社らいむ | 神経伸長促進剤 |
| JP2019218284A (ja) * | 2018-06-18 | 2019-12-26 | オンガネジャパン株式会社 | 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213000A1 (en) * | 1995-03-06 | 1996-09-12 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| US20010056068A1 (en) | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| US20060046982A1 (en) * | 2004-08-26 | 2006-03-02 | Waugh William H | Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease |
| WO2009096505A1 (ja) * | 2008-01-30 | 2009-08-06 | Kyowa Hakko Bio Co., Ltd. | 注意集中力向上剤 |
| WO2010092597A2 (en) * | 2009-02-11 | 2010-08-19 | Lyka Labs Limited | Liposomal citicoline injection |
| ES2345802B1 (es) * | 2009-03-30 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus. |
| ES2906614T3 (es) | 2012-10-30 | 2022-04-19 | Kyowa Hakko Bio Co Ltd | Agente para evitar o mejorar el deterioro de la función cerebral |
-
2013
- 2013-10-30 ES ES13850415T patent/ES2906614T3/es active Active
- 2013-10-30 NZ NZ707081A patent/NZ707081A/en unknown
- 2013-10-30 EP EP13850415.4A patent/EP2914270B1/en active Active
- 2013-10-30 US US14/435,984 patent/US10905705B2/en active Active
- 2013-10-30 JP JP2015538829A patent/JP6166786B2/ja active Active
- 2013-10-30 PL PL13850415T patent/PL2914270T3/pl unknown
- 2013-10-30 WO PCT/JP2013/080053 patent/WO2014069667A1/en not_active Ceased
- 2013-10-30 CA CA2889109A patent/CA2889109C/en active Active
- 2013-10-30 AU AU2013339058A patent/AU2013339058B2/en active Active
-
2020
- 2020-12-30 US US17/138,742 patent/US11738037B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2914270A4 (en) | 2016-03-16 |
| JP2015535241A (ja) | 2015-12-10 |
| US20210113601A1 (en) | 2021-04-22 |
| JP6166786B2 (ja) | 2017-07-19 |
| PL2914270T3 (pl) | 2022-03-14 |
| CA2889109A1 (en) | 2014-05-08 |
| US20150306125A1 (en) | 2015-10-29 |
| CA2889109C (en) | 2020-09-01 |
| US10905705B2 (en) | 2021-02-02 |
| ES2906614T3 (es) | 2022-04-19 |
| WO2014069667A1 (en) | 2014-05-08 |
| AU2013339058B2 (en) | 2017-09-07 |
| AU2013339058A1 (en) | 2015-05-07 |
| EP2914270B1 (en) | 2022-01-12 |
| US11738037B2 (en) | 2023-08-29 |
| EP2914270A1 (en) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500561A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| MX379044B (es) | Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal. | |
| NZ707081A (en) | Agent for preventing or improving decline in brain function | |
| MX353874B (es) | Gotas para los ojos que contienen diquafosol. | |
| SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
| WO2013022846A3 (en) | Flavonoid compounds | |
| WO2013178965A3 (fr) | Principes actifs activateurs de la mitophagie des cellules cutanées et utilisation pour améliorer l'état de la peau | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| PL2854910T3 (pl) | Poziomy ceramidu w leczeniu i zapobieganiu infekcjom | |
| IN2014KN02914A (OSRAM) | ||
| EP2749582A4 (en) | FLUOROUS COPOLYMER AND SURFACE MODIFICATOR THEREFOR AS ACTIVE SUBSTANCE | |
| JP2015535241A5 (OSRAM) | ||
| MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
| HUE056409T2 (hu) | PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására | |
| MX353580B (es) | Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel. | |
| MY182591A (en) | Compositions for use in treating eye disorders using dipyridamole | |
| EP2905337A4 (en) | AMPHIREGULIN SPECIFIC DOUBLE HELIX OLIGO RNA, DOUBLE HELIX OLIGO RNA STRUCTURE WITH THE DOUBLE HELIX OLIGO RNA AND COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASES THEREWITH | |
| IN2014MN01551A (OSRAM) | ||
| EA201500778A1 (ru) | Композиция по уходу за кожей | |
| WO2014031982A3 (en) | Methods and compositions for treating pain | |
| NZ706862A (en) | Agent for preventing or improving decline in brain function | |
| WO2013107687A3 (fr) | Compositions dermo-cosmétiques à base d'une association synergique d'argent colloïdal et d'acide désoxyribonucléique | |
| HK1203379A1 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | |
| UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
| WO2013038200A3 (en) | Neurodevelopmental disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2020 BY CPA GLOBAL Effective date: 20190912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2023 BY CPA GLOBAL Effective date: 20220915 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2024 BY CPA GLOBAL Effective date: 20230914 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250918 |